J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences
Johnson & Johnson will acquire Ollin for $2.2 billion upfront, with the potential for milestone payments of up to about $1.13 billion, the drugmaker said.
This is a brief. The reporting belongs to CNBC — read the complete story, with full context and credits, at the source.
Read the full story at CNBC ↗cnbc.com
More from the Business desk
Just in

Beckham firm sues after fragrance found for sale in Poundland
Just in